# Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

> **NCT00827177** · PHASE1 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 87 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Treatment with ARQ 197 in combination with sorafenib

## Key facts

- **NCT ID:** NCT00827177
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-09
- **Final completion:** 2013-05
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2014-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00827177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00827177, "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00827177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*